Chris L Brady

US Patent:

20190204320, Jul 4, 2019

Filed:

May 17, 2017

Appl. No.:

16/302343

Inventors:

- Durham NC, US
Chris Brady - Durham NC, US
Yingmiao Liu - Durham NC, US
Herbert Hurwitz - Durham NC, US
Kouros Owzar - Durham NC, US
Alexander Sibley - Durham NC, US
Chen Jiang - Durham NC, US
Ace Hatch - Durham NC, US
Mark Starr - Durham NC, US

Assignee:

Duke University - Durham NC

International Classification:

G01N 33/574
A61P 35/00
C07K 16/22
C07K 16/28

Abstract:

Methods of predicting responsiveness of a cancer in a subject to a cancer therapy including a VEGF targeting agent are provided. The methods may include obtaining a sample from the subject, determining an expression level of at least one biomarker selected from the group consisting of VEGF-D and PlGF in a sample from the subject, comparing the expression level of the biomarker in the sample to a reference level of the biomarker, and predicting the responsiveness of the cancer to treatment with the cancer therapy including a VEGF targeting agent. Optionally, the methods may further include administering a VEGF target agent and/or an anticancer or chemotherapy agent to the subject. Additional methods of prognosing and treating a cancer in a subject are also provided.